Hyperfine, Inc. HYPR

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
37/100
Developing

Ranked against 159 peers in Medical Devices

About Hyperfine, Inc.

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. … Full HYPR analysis →

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.87). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.89). Margin expansion confirms commercial leverage is building.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.35). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.27). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
25
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where HYPR ranks in Medical Devices

Hyperfine, Inc. ranks #112 of 160 scored companies in Medical Devices by moat score — the top 70%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
108 enVVeno Medical Corporation NVNO 38/100 Developing
109 Accelerate Diagnostics, Inc. AXDX 38/100 Developing
110 NANO-X IMAGING LTD NNOX 38/100 Developing
111 Lifeward Ltd. LFWD 38/100 Developing
112 Hyperfine, Inc. HYPR 37/100 Developing
113 Standard BioTools Inc. LAB 36/100 Developing
114 Rapid Micro Biosystems, Inc. RPID 36/100 Developing
115 Vicarious Surgical Inc. RBOT 36/100 Developing
116 Senseonics Holdings, Inc. SENS 36/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How HYPR scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 25 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 33 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 53 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 51 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 42 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 13 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding HYPR's moat

What is Hyperfine, Inc.'s moat score?

Hyperfine, Inc. (HYPR) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #112 of 160 scored companies in Medical Devices, the top 70%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is FCF Quality & Cash Conversion (53/100) and its weakest is Growth Durability (13/100).

How does Hyperfine, Inc. compare with other Medical Devices companies?

Hyperfine, Inc. ranks #112 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Lifeward Ltd. (LFWD) at 38 just above it and Standard BioTools Inc. (LAB) at 36 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Hyperfine, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Hyperfine, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and HYPR scores: Pricing Power & Consumable Moat (25), R&D Pipeline & Capital Returns (33), FCF Quality & Cash Conversion (53), Commercial Execution (51), Capital Structure & Resilience (42), Growth Durability (13). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000